Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 90

Similar articles for PubMed (Select 11740713)

1.

The effect of garlic supplements on the pharmacokinetics of saquinavir.

Piscitelli SC, Burstein AH, Welden N, Gallicano KD, Falloon J.

Clin Infect Dis. 2002 Jan 15;34(2):234-8. Epub 2001 Dec 5.

2.

Garlic reduces saquinavir blood levels 50%; may affect other drugs.

James JS.

AIDS Treat News. 2001 Dec 21;(375):2-3. No abstract available.

PMID:
11810949
4.

Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.

Mouly SJ, Matheny C, Paine MF, Smith G, Lamba J, Lamba V, Pusek SN, Schuetz EG, Stewart PW, Watkins PB.

Clin Pharmacol Ther. 2005 Dec;78(6):605-18.

PMID:
16338276
5.

Effect of food and ranitidine on saquinavir pharmacokinetics and gastric pH in healthy volunteers.

Kakuda TN, Falcon RW.

Pharmacotherapy. 2006 Aug;26(8):1060-8.

PMID:
16863482
6.

Garlic supplements can impede HIV medication.

[No authors listed]

J Am Coll Surg. 2002 Feb;194(2):251. No abstract available.

PMID:
11848645
7.

Garlic supplements can impede HIV medication.

Sussman E.

AIDS. 2002 Jun 14;16(9):N5. No abstract available.

PMID:
12090243
8.

Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.

Ribera E, Azuaje C, Lopez RM, Domingo P, Curran A, Feijoo M, Pou L, Sánchez P, Sambeat MA, Colomer J, Lopez-Colomes JL, Crespo M, Falcó V, Ocaña I, Pahissa A.

J Antimicrob Chemother. 2007 Apr;59(4):690-7. Epub 2007 Feb 16.

9.

Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects.

Singh K, Dickinson L, Chaikan A, Back D, Fletcher C, Pozniak A, Moyle G, Nelson M, Gazzard B, Herath D, Boffito M.

Clin Pharmacol Ther. 2008 Jun;83(6):867-72. Epub 2007 Sep 26.

PMID:
17898705
10.

Drug-drug interaction study of ketoconazole and ritonavir-boosted saquinavir.

Kaeser B, Zandt H, Bour F, Zwanziger E, Schmitt C, Zhang X.

Antimicrob Agents Chemother. 2009 Feb;53(2):609-14. doi: 10.1128/AAC.00769-08. Epub 2008 Nov 17.

11.

Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily.

Autar RS, Ananworanich J, Apateerapong W, Sankote J, Hill A, Hirschel B, Cooper D, Lange J, Phanuphak P, Ruxrungtham K, Burger D.

J Antimicrob Chemother. 2004 Oct;54(4):785-90. Epub 2004 Aug 25.

12.

Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen.

Boffito M, Kurowski M, Kruse G, Hill A, Benzie AA, Nelson MR, Moyle GJ, Gazzard BG, Pozniak AL.

AIDS. 2004 Jun 18;18(9):1291-7.

PMID:
15362661
13.

Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers.

Winston A, Back D, Fletcher C, Robinson L, Unsworth J, Tolowinska I, Schutz M, Pozniak AL, Gazzard B, Boffito M.

AIDS. 2006 Jun 26;20(10):1401-6.

PMID:
16791014
14.

Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors.

Washington CB, Flexner C, Sheiner LB, Rosenkranz SL, Segal Y, Aberg JA, Blaschke TF; AIDS Clinical Trials Group Protocol (ACTG 378) Study Team.

Clin Pharmacol Ther. 2003 May;73(5):406-16.

PMID:
12732841
16.

Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir.

Stephan C, von Hentig N, Kourbeti I, Dauer B, Mösch M, Lutz T, Klauke S, Harder S, Kurowski M, Staszewski S.

AIDS. 2004 Feb 20;18(3):503-8.

PMID:
15090803
17.

The pharmacokinetics, safety and efficacy of boosted saquinavir tablets in HIV type-1-infected pregnant women.

van der Lugt J, Colbers A, Molto J, Hawkins D, van der Ende M, Vogel M, Wyen C, Schutz M, Koopmans P, Ruxrungtham K, Richter C, Burger D; SARA study team.

Antivir Ther. 2009;14(3):443-50.

PMID:
19474478
18.

Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe.

Schmitt C, Hofmann C, Riek M, Patel A, Zwanziger E.

Pharmacotherapy. 2009 Oct;29(10):1175-81. doi: 10.1592/phco.29.10.1175.

PMID:
19792991
19.

Lack of in vivo correlation between indinavir and saquinavir exposure and cytochrome P450 3A phenotype as assessed with oral midazolam as a phenotype probe.

Robertson SM, Formentini E, Alfaro RM, Falloon J, Penzak SR.

Pharmacotherapy. 2006 Aug;26(8):1051-9.

PMID:
16863481
20.

Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients.

Boffito M, Dickinson L, Hill A, Back D, Moyle G, Nelson M, Higgs C, Fletcher C, Gazzard B, Pozniak A.

J Acquir Immune Defic Syndr. 2004 Nov 1;37(3):1376-84.

PMID:
15483467
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk